Tag Archives: TGTX

Wednesday’s Midday Movers: Twitter (TWTR), Alcoa (AA), TG Therapeutics (TGTX), SunPower (SPWR), First Solar (FSLR)

So far Wednesday, July 8, NASDAQ is down -0.12% and the S&P is down -0.51%. Here are this morning’s most active stocks: Twitter (TWTR – Research Report), Alcoa (AA – Research Report), TG Therapeutics (TGTX – Research Report), SunPower (SPWR

Tuesday’s Midday Stock Update: Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Bluebird Bio (BLUE), Cytokinetics (CYTK), Novagold Resources New (NG)

So far Tuesday, July 7, NASDAQ is up 2.11% and the S&P is up 0.93%. Here are this morning’s most active stocks: Inovio Pharmaceuticals (INO – Research Report), TG Therapeutics (TGTX – Research Report), Bluebird Bio (BLUE – Research Report),

Friday’s Midday Movers: Dynavax (DVAX), Zynga (ZNGA), TG Therapeutics (TGTX), Harley-Davidson (HOG), Pan American Silver (PAAS)

So far Friday, May 29, NASDAQ is up 0.12% and the S&P is down -1.33%. Here are this morning’s most active stocks: Dynavax (DVAX – Research Report), Zynga (ZNGA – Research Report), TG Therapeutics (TGTX – Research Report), Harley-Davidson (HOG

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX) and Allogene Therapeutics (NASDAQ: ALLO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Allogene Therapeutics (ALLO – Research Report) with bullish sentiments. TG Therapeutics (TGTX) H.C. Wainwright analyst

B.Riley FBR Believes TG Therapeutics (NASDAQ: TGTX) Won’t Stop Here

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (TGTX – Research Report) yesterday and set a price target of $37.00. The company’s shares closed last Friday at $19.30, close to its 52-week high of $21.59. According

H.C. Wainwright Believes TG Therapeutics (NASDAQ: TGTX) Still Has Room to Grow

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $32.00. The company’s shares closed last Tuesday at $20.30, close to its 52-week high